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Vesicular systems for delivering conventional small organic molecules and larger 
macromolecules to and through human skin 
Abstract 
 The history of using vesicular systems for drug delivery to and through skin 
started nearly three decades ago with a study utilizing phospholipid liposomes to improve 
skin deposition and reduce systemic effects of triamcinolone acetonide. Subsequently, 
many researchers evaluated liposomes with respect to skin delivery, with the majority of 
them recording localized effects and relatively few studies showing transdermal delivery 
effects. Shortly after this, Transfersomes were developed with claims about their ability 
to deliver their payload into and through the skin with efficiencies similar to 
subcutaneous administration. Since these vesicles are ultradeformable, they were thought 
to penetrate intact skin deep enough to reach the systemic circulation. Their mechanisms 
of action remain controversial with diverse processes being reported. Parallel to this 
development, other classes of vesicles were produced with ethanol being included into 
the vesicles to provide flexibility (as in ethosomes) and vesicles were constructed from 
surfactants and cholesterol (as in niosomes). Thee ultradeformable vesicles showed 
variable efficiency in delivering low molecular weight and macromolecular drugs. This 
article will critically evaluate vesicular systems for dermal and transdermal delivery of 
drugs considering both their efficacy and potential mechanisms of action.   
Keywords 
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1. Introduction 
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 The skin is the largest single organ in the body and so provides formulators with a 
large surface area for drug application. Transdermal drug delivery has many potential 
advantages over other routes of administration. These include the avoidance of gastro-
intestinal tract problems and hepatic first pass effects and improvement in patient 
compliance.  Unfortunately, the barrier nature of skin presents difficulties for delivering 
many drugs into and through it [1]. Various approaches have been utilized to improve 
transdermal delivery [2-3].  These include the use of chemical penetration enhancers [4], 
optimization of chemical potential of the drug, for example by increasing the driving 
force through supersaturation [5-6], electrically driving molecules into or through the 
tissue employing iontophoresis [7], physically disrupting the skin structure, for example 
by electroporation or sonophoresis [8-9] or incorporation of the drug in microemulsions 
[10-11]. Vesicular drug delivery systems such as Liposomes, Niosomes, Ethosomes and 
Transfersomes provide an alternative for improved drug delivery to and through the skin 
[12-17]. 
 Variable functions have been reported for vesicular systems as skin drug delivery 
systems [18].  They can provide a localized depot in the skin and reduce the amounts of 
drug permeating into the systemic circulation thus minimizing the unwanted effects.  
They may also provide targeted delivery through the appendageal pathway (hair follicles 
and sweat ducts). Additionally, vesicles can enhance transdermal drug delivery, 
increasing systemic drug concentrations. Indeed, some vesicles may possess several of 
the above functions, with the main effect depending on the type of vesicle as well as the 
application protocol. This diversity becomes greater when considering the mechanisms of 
action of these nano-structures as skin drug delivery systems.  Accordingly, the aim of 
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this article is to provide a critical review of vesicles as skin drug delivery systems with 
emphasis on the types of vesicles as well as the nature of the encapsulated drug. 
  
2. Body 
2.1. Types of vesicular systems 
 Alternative terminology has been used to describe vesicular systems but all 
researchers agree that they are of a similar morphology but with different functions 
and/or compositions [13-16].  
 Liposomes are vesicles in which one or more lipid bilayer(s) entrap an aqueous 
volume.  Their major components are usually phospholipids with or without cholesterol. 
The stratum corneum lipid liposomes (SCLL) are vesicular systems made of lipids with a 
composition similar to the lipids found in the outer layer of human skin, the stratum 
corneum.  Transfersomes (ultradeformable vesicles) are structurally similar to liposomes 
but they differ in function (see below); again phospholipids are the major components but 
an additional surfactant acts as an edge activator to modify elasticity and increase 
deformability.  Ethosomes are phospholipid vesicles, which include ethanol to increase 
elasticity, whereas niosomes comprise surfactants together with cholesterol and may 
include small proportions of phospholipids. 
 
2.2. Vesicular skin drug delivery of conventional small organic molecules 
 Vesicular skin delivery of such compounds could produce localized effect, deliver 
the drug into or through the skin appendages or provide transdermal delivery with 
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increased systemic effects. These effects are considered below with a critical appraisal of 
the relevant literature. 
 
2.2.1. Localized effects 
 Steroidal drugs in liposomes have been extensively studied; the localizing effect 
of liposomes was recorded for steroids in the first ever report on vesicles as skin drug 
delivery systems [12]. In this work, dipalmitoylphosphatidylcholine (DPPC) and 
cholesterol (CH) vesicles increased the deposition of triamcinolone acetonide in the 
epidermis and dermis, and reduced percutaneous absorption compared with a standard 
ointment [12].  Incorporating the same formulation in a gel dosage form, similar findings 
were observed relative to a gel containing free drug and the components of liposomes at 
the same concentrations [19].  These initial findings reflected the importance of 
liposomal encapsulation and hence good entrapment efficiency of the drug in the vesicle 
for efficient skin drug delivery.  Similar findings were reported for progesterone and 
econazole delivered from liposomes with a similar lipid composition [20].  In contrast, 
the topical input of 5 -dihydrotestosterone from similar vesicles was inferior to that from 
an acetone solution containing the same drug concentration when assessed by monitoring 
the size of the flank organs of the female hamster [21].  This contradiction was attributed 
to four possible factors; first, the use of different steroids; second, the first group 
monitored delivery by measuring skin deposition whilst the later studies measured a 
biological effect; then, the studies used different animals and finally, the schemes of 
application were different. An alternative explanation is that both groups used equal drug 
concentrations rather than equal thermodynamic activity for their controls and that the 
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biological effect on the hamster flank organs may require systemic drug delivery rather 
than a liposome-mediated localized effect. The deposition of hydrocortisone into human 
skin was significantly higher after application of phosphatidylcholine (PC)/CH liposomes 
compared with an emulsion ointment form.  The improved skin deposition and reduced 
systemic effects were further confirmed by monitoring blanching effects and determining 
the pharmacokinetic parameters of hydrocortisone [22]. Similarly, SCLL and 
phospholipid vesicles showed better skin deposition of corticosteroids with the former 
being superior. The anti-inflammatory effects from nano-structural delivery paralleled the 
skin accumulation results [23]. 
 In contrast to the above, it was reported that liposomal encapsulation facilitated 
both the retention and permeation of triamcinolone acetonide compared with an ointment 
formulation [24].  This discrepancy could be due to the use of different membranes; 
permeability differences between species and especially the relatively poor correlation 
seen between animal skin models and human skin can make direct comparisons between 
laboratory protocols problematic.   
 In addition to steroids, the localizing effects of liposomes have also been sought 
for treating various skin conditions such as psoriasis.  Thus, radiotracer studies in mice 
revealed improved skin accumulation of tacrolimus from a vesicle-containing lotion 
compared with intravenous injection of a solution or the liposomal formulation [25].  In 
addition to the 9-fold increase in skin levels of the drug following topical nano-aggregate 
delivery compared with systemic delivery, the vesicular formulation also prevented 
delayed-type hypersensitivity reactions seen with systemic provision. 
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 Local anesthetics are another group of low molecular weight drugs for which 
liposomal encapsulation was researched for dermal and transdermal delivery.  Using the 
pin-prick assay, prolonged anesthesia from tetracaine-containing liposomes was shown 
with a cream control formulation being ineffective [26].  Using the same assay, 
liposomes prolonged lidocaine anesthesia compared with a conventional cream with a 
higher deposition in the epidermis and dermis being recorded [27]. The improved 
anesthetic effect after vesicular delivery could be thus attributed to improved skin 
accumulation.  In another report, liposomal tetracaine increased both drug permeation 
through, and deposition into, human skin compared to an ointment containing the same 
drug concentration [28].  The anesthesia recorded after liposomal application was even 
stronger and deeper than that obtained from a commercial eutectic mixture of local 
anesthetics (EMLA, 2.5 % lidocaine and 2.5% prilocaine) in humans [29-30]. 
 The above studies all employed liposomes made of phospholipids or skin lipids.  
Planas et al (1992) reported an improved anesthetic effect of lidocaine and tetracaine 
from Transfersomes.  In vivo studies employed rats and humans to assess anesthesia after 
topical application of Transfersomes (PC plus sodium cholate), liposomes (PC) and drug 
solution [31].  It is important to note that the authors applied the tested formulations 
under occlusion for 25 minutes, which is against the recommended open application 
protocol.  Transfersomes produced enhanced anesthesia compared with drug solution or 
traditional liposomes.  Surprisingly, topically-applied anesthetic Transfersomes generated 
an effect equivalent to that created after subcutaneous injection of the same formulation. 
 The skin delivery of 5-fluorouracil (5-FU) from similar Transfersomes was 
investigated after application of a finite dose with saturated aqueous solution used as the 
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control [32].  The study employed aqueous or water/ethanol (50% v/v) receptor solutions.  
The results (Figure 1) showed a marginal increase in transepidermal delivery into the 
aqueous receptor.  However, the ethanolic receptor significantly increased drug 
permeation when using the vesicles.  These findings were taken as evidence for improved 
deposition of the drug in the skin as ethanol is expected to diffuse into the tissue 
disrupting deposited vesicles and extracting the drug.  The skin distribution from 
Transfersomes was described as dose dependent [33]; the use of finite or infinite doses 
can thus affect the relative proportion of localized to transdermal drug amounts and hence 
optimization of the applied dose is an important facet of Transfersomal action.  
 
Insert Figure 1 
 Elastic niosomes of Tween 61 and cholesterol were recently developed by 
incorporating ethanol at 25%. These vesicles were successful in delivering the anti-
inflammatory drug diclofenac diethylammonium into and through the skin when 
compared to non-elastic niosomes which increased the deposition of the drug only [34]. 
The improved transdermal effect could have resulted from the enhancing effect of 
ethanol. 
 
2.2.2. Targeted delivery to skin appendages 
 The above literature determined localizing effects of vesicular systems on the 
basis of increased drug deposition into the stratum corneum and viable epidermis. Other 
workers have studied the potential of such nano-structures for targeting the appendages, 
especially to the pilosebaceous units (hair follicles with their associated sebaceous 
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glands).  This area was extensively reviewed by Lauer et al (1996) and Lauer (1999) [35-
36]. 
 Employing the hamster ear model, liposomes of PC, CH and phosphatidylserine 
(PS) delivered the fluorescent hydrophilic dye, carboxyfluorescein, into the 
pilosebaceous units.  They were more efficient than aqueous solutions even after 
incorporation of 10% ethanol or 0.05% sodium lauryl sulphate, or using propylene glycol 
as the donor vehicle [37-38]. 
 Targeted delivery of cimetidine into the pilosebaceous glands and other skin strata 
of the Syrian male hamster ear was recorded after topical application of the drug in 50% 
aqueous ethanol, niosomes, or in liposomes.  Monitoring the anti-androgenic effect, the 
first two formulations were pharmacologically active with the later being ineffective.  
The authors explained the lack of a biological effect from the phospholipid vesicles, 
despite increased drug provision into the tissue, on the basis that the negative charge of 
lipids can inactivate the drug by forming an ion pair with it at pH 5.5 (the pH of the 
formulation) [39].  Autoradiography revealed the presence of considerable amounts of 
caffeine in the appendages after topical application of liposomes to rat skin but most of 
the drug was localized in the epidermis [40]. 
 In contrast to the above reports, neither liposomes nor mixed micelles provided 
any advantage over an ethanolic gel with regard to follicular delivery of isotretinoin.  
This finding was attributed to the highly lipophilic nature of the drug which would 
intrinsically target the sebaceous gland [41].  However, the use of an ethanolic 
preparation as the control may be responsible for possible misleading results since 
ethanol is capable of enhancing the follicular delivery through partial solubilisation of the 
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sebum or softening of the material in the duct, which could result in the ethanolic control 
producing significant drug input. The control was thus shown to be equivalent to the 
other formulations.  Whilst these findings could suggest a positive targeting effect of 
liposomes and mixed micelles, we can only conclude that they were as effective as the 
ethanolic gel.  
 Vesicular preparations were found to be superior in the treatment of acne vulgaris 
compared with conventional preparations including alcoholic lotions [42-43].  This study 
provides strong evidence for effective vesicular targeting to skin appendages. 
 Further, in vitro permeation through hamster flank skin and in vivo deposition in 
hamster ear recently demonstrated the potential of liquid-state liposomes and niosomes 
for successfully delivering finasteride to the pilosebaceous unit [44]. 
 
2.2.3. Improved transdermal delivery 
 Despite concentrating on the localizing effect of liposomes with improved drug 
deposition into skin and its appendages, some early reports recorded improved 
transdermal delivery from these nano-aggregates.  After topical application of finite doses 
of liposomes to hairless mouse skin in vitro, it was reported that vesicles can provide 
greater permeation of lipophilic drugs compared to an aqueous solution [45].  
Formulations containing unilamellar soya-lecithin/CH liposomes advanced the 
percutaneous absorption of methyl nicotinate compared with an aqueous solution or gel 
formulations [46].  Vesicles containing Epikuron 200, a phospholipid with unsaturated 
alkyl side chains (fluid liposomes), produced high percutaneous absorption and tissue 
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distribution rather than skin accumulation.  Renal elimination of inulin was 20-fold 
higher after usage of such liposomes compared to delivery from aqueous solution [47].   
 While researchers were reporting mainly localized and rarely transdermal effects 
of liposomes, Cevc and Blume (1992) [13] claimed that Transfersomes can penetrate 
intact to the deep layers of the skin and may progress far enough to reach the systemic 
circulation.  Importantly, they recommended that, for successful delivery, Transfersomes 
must be applied under non-occlusive conditions, although a deviation from this protocol 
can be found [31] where improved anesthesia was reported after occluded treatment with 
anesthetic Transfersomes.  Transfersomes improved the regio-specificity and the 
biological activity of the corticosteroids hydrocortisone, dexamethasone and 
triamcinolone acetonide, in vivo.  The effect depended on the applied dose and it was 
concluded that this carrier can target the drug into the viable skin and, when used in a 
higher dose, can distribute the medicament throughout the body [33]. Transfersomes 
provided suppression of arachidonic acid-induced oedema with an efficiency equivalent 
to a lotion containing 5-times the drug concentration of that in deformable vesicles, after 
0.5 hour.  Subsequently, after 2 hours, the Transfersome formulation was more 
efficacious than the lotion.  Evaluating standard liposomes, no oedema suppression was 
found after 0.5 hour.  After 2 hours, however, liposomes produced a measurable 
suppression.  The effect of liposomes (after 2 hours) was about one third that of 
deformable vesicles and about half that of the lotion (with 5-times more drug).  The 
authors stated that the late effect of the vesicle formulation arose from free drug 
permeation following its release from liposomes [33].  However, if this explanation is 
valid, vesicles would be expected to provide one fifth of the efficacy of the lotion 
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(containing free drug), unless there is some penetration enhancing effect for such 
liposomes. 
 In addition, the arachidonic acid-induced oedema suppression test (acute murine 
ear oedema model) was used to evaluate the anti-inflammatory effect of Cu, Zn-
superoxide dismutase after topical application in Transfersomes, mixed micelles or 
liposomes.  Of all the tested carriers only Transfersomes significantly reduced oedema 
[48]. 
 In a series of investigations involving an optimized experimental design, estradiol 
skin delivery from a variety of ultradeformable and standard liposomes was investigated 
[49].  The previously optimized ultradeformable formulations employed various edge 
activators (surfactants); PC with sodium cholate (UD1), PC with Span 80 (UD2) and PC 
with Tween 80 (UD3)  [50].  The standard vesicles encompassed pure PC vesicles (non 
rigid liposomes, SL1), PC with CH (membrane stabilized, SL2), and two rigid liposomes 
of DPPC (SL3) and DPPC/CH (SL4).  The studies involved a low dose open application 
of the formulations to human epidermal membrane hydrated by an “open hydration” 
protocol that maintained the transepidermal water gradient and evaluated both the 
transdermal flux and skin deposition. The results (Figure 2) indicated that all types of 
liposomes improved both estradiol deposition into and permeation through the epidermis 
compared with the saturated aqueous control.  The ultradeformable vesicles were better 
than the standard liposomes with respect to transepidermal drug flux but there were no 
significant differences within the different types of nano-carriers with regard to estradiol 
accumulation in the skin.  The ultradeformable liposomes reduced the time of maximum 
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flux (Tmax) by 11-16%.  For the standard liposomes, Tmax was either constant (SL1) or 
increased by 10-20% (SL2-4). 
 
Insert Figure 2 
 The incorporation of a surfactant in liposomes increases the fluidity (flexibility) 
or elasticity of the lipid bilayers [51].  Accordingly, it can be concluded that flexible 
liposomes are more efficient in delivering drugs across the epidermis.  The presence of 
surfactants (edge activators) was considered responsible for vesicle deformability, which 
allows for improved transdermal drug delivery [52-54].  The incorporation of ethanol in 
lipid vesicles (Ethosomes) is an alternative approach to fluidize the lipid membrane and 
thus enhance drug provision [16-17]. Also, flexible niosomes showed higher delivery 
efficiencies compared to rigid niosomes [55-56]. 
 
2.3. Vesicular skin delivery of large molecular weight compounds 
 Recently, the potential of vesicles to deliver large molecules into and through the 
skin has been extensively investigated recently, for molecules ranging from large 
molecular weight peptides to DNA based vaccines. As for the small organic molecules, 
vesicular skin delivery can provide localized effects, deliver the drug into or through the 
skin appendages or promote transdermal delivery with increased systemic effects. 
 
2.3.1. Localized effect 
 Topical delivery of the peptide drug interferon from liposomes was superior to 
that from a water-in-oil emulsion or aqueous solution as revealed by reduced lesion 
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scores from a cutaneous herpes simplex virus guinea pig model.  Interferon delivery from 
SCLL produced greater remission of lesions compared to the input from phospholipid 
liposomes.  With respect to the method of nano-aggregate preparation, those produced by 
a dehydration rehydration (DRV) method were more effective than when prepared by 
mechanical shaking or extrusion [57].  The authors attributed the superiority of DRV 
liposomes to increased drug partitioning into the vesicle, but the advantage could also 
have been due to increased entrapment efficiency.  In a subsequent study the in vitro tape 
stripping of guinea pig skin was used to determine the skin deposition of interferon, with 
the amount of drug permeated also evaluated [58]. Liposomes increased the deposition of 
interferon into stratum corneum and deeper skin strata with no drug detected in the 
receptor.  Again SCLL prepared by DRV were considered superior to other formulations.  
This study indicated that the previously obtained pharmacological effect was due to 
localization of the drug [57].  The deposition of cyclosporin-A into the stratum corneum 
of hairless mice was increased, whilst transdermal absorption reduced, from various 
liposomal formulations compared to drug solutions. The formulations were ranked with 
respect to drug localization as SCLL > phospholipid liposomes > O/W emulsion 
(emulsifier composition similar to lipid content of phospholipid vesicles) > 
hydroalcoholic drug solution (5 mg/ml in 40% ethanol) [59]. This series of investigations 
emphasized the localizing effects of liposomes and highlighted the dependence of 
deposition efficiency on the lipid composition and method of preparation, though it 
should be noted that the animal models used may not reflect delivery into human skin. 
 
2.3.2. Targeted delivery to skin appendages 
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 Liposomal skin deposition of -interferon was monitored in humans, hairless mice 
and hamster skin in vitro.  Vesicles were superior over an aqueous solution containing the 
same amount of the drug.  The greatest accumulation was recorded in hamster skin, 
which possesses the highest follicular density.  It was thus suggested that the follicular 
pathway could be a route for macromolecular drug deposition from liposomes [60]. 
 
2.3.3. Improved transdermal delivery 
 Qualitative immunohistochemical examination revealed that liposome-
encapsulated antibodies (molecular weight 20000-50000 Da) distributed rapidly into the 
deep cutaneous regions of piglet skin in vivo, compared with no penetration after 
application of aqueous solution or empty vesicles.  Quantitative studies using 
radiolabelled markers revealed not only improved deposition into the deep strata but also 
clearly increased transdermal delivery from vesicles compared with aqueous solution [61-
62].  A liposomal formulation of PC and CH augmented the uptake of biologically active 
recombinant human -interferon into the epidermis of viable human skin compared with 
aqueous solution [63].   
 Successful systemic delivery of insulin has been achieved by Transfersomes as 
reported from in vivo mice and human studies.  Drug distribution studies confirmed the 
transfer of 
125
I-insulin across intact skin with subsequent distribution throughout the body 
after topical application of Transfersomes, and pharmacodynamic studies revealed a 
reduction in the blood glucose levels.  The efficiency from the vesicles was comparable 
to that obtained after S.C. injection of the same preparation but with a longer lag time.  
This lag time may be required for vesicle skin penetration.  Both mixed micelles and 
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standard liposome formulations of insulin failed to reduce blood glucose.  It was thus 
concluded that Transfersomes provide non-invasive transdermal delivery of therapeutic 
agents, including insulin [64-66].   
 Successful topical delivery of low molecular weight heparin was reported after 
incorporation into flexible vesicles made of lipids with Tween 80, which bore a surface 
charge. These vesicles were termed flexosomes of which cationic structures were the 
most efficient [67]. 
 Topically applied Transfersomes have been evaluated for topical immunization 
using Gap junction proteins (GJP). The study revealed a rise in specific antibody levels 
marginally higher than those elicited by subcutaneous injections of GJP in 
Transfersomes, mixed lipid micelles or liposomes. The latter two carrier systems give no 
significant biological response after topical administration. Transdermal protein delivery 
by means of Transfersomes increased the relative concentration of anti-GJP IgA in the 
serum [68]. 
 Transfersomes, niosomes (Span 85 and cholesterol, 1:1 w/w) and liposomes (PC 
and CH, 7:3 w/w) were compared for their relative potential in non-invasive transdermal 
delivery of tetanus toxoid (TT). The in vivo study revealed that topical TT-containing 
Transfersomes could elicit an immune response (anti-TT-IgG) equivalent to that 
produced following intramuscularly alum-adsorbed TT-based immunization whilst i.m. 
delivered niosomes and liposomes produced weaker immune responses [69]. 
 A new type of fusogenic vesicles (vesosomes) have been introduced for topical 
immunization. In these, the tetanus toxoid was incorporated into cationic liposomes made 
of PC, dioleoyl phosphatidylethanolamine (DOPE) and dioleoyl trimethyl ammonium 
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propane (DOTAP). These vesicles were subsequently entrapped in an interdigitated lipid 
bilayer to provide vesicles within a vesicle (vesosomes). These aggregates were claimed 
to provide a promising system for transcutaneous immunization [70]. 
 Niosomes made of span 85 and cholesterol and prepared by a reversed phase 
evaporation technique were employed for topical delivery of a DNA vaccine. The DNA 
encoding hepatitis B surface antigen (HBsAg) was encapsulated in niosomes or 
liposomes. Topical application of niosomes produced a comparable serum antibody titer 
and endogenous cytokines levels when compared to intramuscular administration of 
recombinant HBsAg and topical liposomes. This was taken as an indication of the 
potential of niosomes as DNA vaccine carriers for effective topical immunization [71].  
In a follow on study, cationic Transfersomes made of dioleoyl trimethyl ammonium 
propane (cationic lipid) with sodium deoxycholate were likewise successfully used for 
transdermal delivery of the hepatitis B DNA vaccine. Topical application of DNA loaded 
cationic Transfersomes elicited a comparable serum antibody titer and endogenous 
cytokines levels as produced after intramuscular recombinant HBsAg administration 
[72].The Span 80 based ultradeformable vesicles which was initially optimized by El 
Maghraby et al (2000a) [50] have also  recently been used for topical immunization. The 
results suggested that hepatitis B loaded ultradeformable vesicles are able to provide 
protective immune response [73-74]. 
 The efficiency of Hepatitis B surface antigen (HBsAg)-loaded ethosomes was 
evaluated for transcutaneous immunization against Hepatitis B. Transcutaneous delivery 
potential of the antigen-loaded system using human cadaver skin demonstrated a much 
higher skin permeation of the antigen in comparison to conventional liposomes and 
 17 
soluble antigen preparations. Topically applied HBsAg-loaded ethosomes to mice 
showed a robust systemic and mucosal humoral immune response compared to 
intramuscularly administered alum adsorbed HBsAg suspension, topically applied plain 
HBsAg solution and hydroalcoholic solution of HBsAg. It was thus concluded that 
HBsAg-loaded ethosomes can generate a protective immune response and their ability to 
traverse and target the immunological milieu of the skin may find application in the 
development of a transcutaneous vaccine against the Hepatitis B virus (HBV) [75]. 
 
2.4. Mechanisms of action of vesicles as skin drug delivery systems 
 Various mechanisms have been reported for improved transdermal drug delivery 
from vesicular systems. These mechanisms are summarized in Figure 3. This section will 
critically evaluate the reported mechanisms by highlighting both positive and negative 
evidence for each mechanism.  
 
Insert Figure 3 
 
2.4.1. Free drug mechanism (see Figure 3 at A) 
 According to this process, the drug has to be released from the vesicles before 
independent permeation into and through the skin [45]. In this case, vesicles can be 
considered only as carriers that can control drug release with drug permeation depending 
on its physicochemical chemical characteristics. To investigate this possibility, the 
transepidermal flux profile obtained from different liposome formulations was compared 
with the corresponding in vitro drug release profile.  For all preparations, the peak flux of 
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estradiol through skin appeared at a time during which drug release was negligible.  This 
suggests that a free drug mechanism did not operate for the tested standard and 
deformable liposome formulations [49].   
2.4.2. Penetration enhancing mechanism (see Figure 3 at B) 
 According to this mechanism, vesicle components may enter the skin as 
monomers disrupting the packing characteristics of the SC lipid bilayers and thus 
enhancing drug permeation. The penetration enhancing effect of egg lecithin (included in 
a drug solution in propylene glycol) was first recorded two decades ago, after in vitro and 
in vivo animal studies.  It was concluded that lecithin enhances the transdermal delivery 
of bunazosin hydrochloride by lowering the permeability barrier of the skin [76]. This 
early finding suggested the possible accelerant effect of a liposome component. 
 Freeze fracture electron microscopy and small angle X-ray scattering studies, 
performed 48 hours after incubating human SC in liposome dispersions, revealed that 
vesicle components can change the ultrastructure of the intercellular lipid regions, 
indicative of penetration enhancing effects.  It was concluded that vesicles made of lipids 
with relatively small hydrophilic head groups can produce marked interaction with 
human stratum corneum lipids in vitro [77]. After application of soybean PC liposomes to 
human epidermis reconstituted in vitro, electron microscopy showed the presence of 
dose-dependent alterations in the morphology of both the SC and the viable epidermis 
with shrunken lipid droplets formed between the corneocytes.  This supported further the 
previous findings of an enhancing action from liposomes [78].   
 In another study, differential scanning calorimetric investigations performed to 
human SC treated (non-occlusively) with dimyristoylphosphatidylcholine (DMPC) 
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liposomes showed changes in the enthalpy of the lipid-related transitions of the SC [79].  
In addition, depending on composition, vesicles may produce an enhancing effect (shown 
by skin pre-treatment), may penetrate deep into the stratum corneum or may fuse and mix 
with skin lipid.  Liposomes containing dioleylphosphatidylethanolamine (DOPE) or lyso-
PC produced the greatest effect [80].  Vesicles containing DOPE can fuse and mix with 
skin lipids and loosen their structure.  This was evidenced by the interactions of these 
vesicles with stratum corneum lipid liposomes; it was suggested that the conical shape of 
DOPE was essential for this effect.  Both the PE and dioleyl moieties were essential, as 
nano-structures containing PE (with other fatty acid chains) provided lower enhancing 
effects compared with the DOPE liposomes [80]. More recently, the same group recorded 
deeper penetration of a lipophilic fluorescent probe into SC after application of PC 
liposomes containing 32% ethanol compared with ethanol-free vesicles.  Ethanol did not 
affect the penetration pattern from DOPE-containing liposomes, but addition of ethanol 
increased the mixing of both vesicles with SCLL.  In addition, ethanol-containing nano-
structures (both types) destabilized skin lipid-based liposomes as evidenced by increased 
calcein release from SCLL preparations compared with control (containing the same 
concentration of ethanol).  These studies provide further evidence for the penetration 
enhancing effect of liposome components [81].    
 Phospholipid solutions in propylene glycol increased percutaneous absorption of 
indomethacin and the order of activity was; phosphatidylglycerol (PG) > 
phosphatidylethanolamine (PE) > PC > phosphatidylserine (PS) > phosphatidic acid (PA) 
> phosphatidylinositol (PI) > control > sphingomyelin (SM) [82].   The phospholipids 
were classified into three groups; the first included PG, PE and PC with head groups 
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having a strong enhancing effect, the second contained PS, PA and PI, classified as weak 
promoters and the third has SM which is not an enhancer.  When repeating the same 
study on silastic membranes instead of skin, no phospholipid accelerated the permeation 
of the drug.  Furthermore, PG, PE, PC or SM did not significantly affect the percutaneous 
absorption of indomethacin through skin lacking stratum corneum.  This clearly indicated 
that phospholipids act directly on the permeability barrier of SC [82].  In a similar study, 
the effects of the hydrophobic entity in the phospholipids were probed [83]. It was 
suggested that phospholipids containing unsaturated fatty acid chains in the hydrophobic 
group are strong promoters.  As in the previous studies, the authors showed that the 
phospholipids work by directly affecting the SC. 
 The effect of skin pretreatment with PC liposomes on the transdermal delivery of 
a variety of corticosteroids from creams was evaluated by the human skin blanching 
assay.  The pre-treatment increased the blanching response and reduced the tachyphylaxis 
for all preparations except clobetasone butyrate.  The authors explained this effect on the 
basis that PC may form a thin film on the skin surface into which corticosteroids can 
preferentially partition, or that PC can partition into SC and thus enhance delivery by 
influencing the partitioning of corticosteroid into skin [84]. 
 Negative findings regarding the penetration enhancing mechanism have also been 
reported, some examples of which are summarized below.  No accelerant effect was 
found for SCLL after application of the empty vesicles in combination with free 
interferon [57].  Skin pretreatment with empty phospholipids or skin lipid liposomes did 
not give the advantages of encapsulated drug, showing no enhancement for both 
hydrophilic and lipophilic drugs [85]. It was thus concluded that the suggestion that 
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liposomes interact with SC is invalid.  It was further proposed that vesicles must at least 
be applied concomitantly with the drug or that the drug must be encapsulated within 
them. 
 Employing a pre-treatment protocol with empty vesicles, we evaluated the 
penetration enhancing effect of a variety of vesicles [49], including both ultradeformable 
and standard formulations. The ultradeformable (UD) systems included PC with sodium 
cholate (UD1), PC with Span 80 (UD2) and PC with Tween 80 (UD3) which were 
previously optimized.  The standard liposomes (SL) encompassed pure PC vesicles (non 
rigid, SL1), PC with CH (membrane stabilized, SL2), and two rigid liposomes of DPPC 
(SL3) and DPPC/CH (SL4).  The results indicated a possible accelerant effect only for 
the non-rigid PC vesicles (SL1) for which drug flux improved 4-fold.  However, 
comparing this promotion with the relative flux obtained after application of estradiol 
encapsulated in the same formulation (8-fold) it was concluded that the penetration 
enhancing mechanism is not the only (or main) mechanism operating.  For other 
traditional and ultradeformable systems, skin pre-treatment was not effective, thus 
excluding an accelerant effect and suggesting other mechanisms for the improved skin 
delivery from such formulations.  
 The importance of vesicular structure for transdermal delivery from liposomes 
was investigated by comparing estradiol skin delivery from standard and ultradeformable 
vesicles with that obtained from propylene glycol solutions containing the same vesicular 
components. All systems were at the same thermodynamic activity.  The results indicated 
the importance of the colloidal structure and these findings again excluded a major role 
for a penetration promoting mechanism in improved skin delivery from such liposomes 
 22 
[86]. More recently, the efficiency of elastic and rigid niosomes was investigated and it 
was reported that drug molecules must be applied together with, and entrapped within, 
the nano-aggregates themselves. It was suggested that elastic vesicles act as drug carrier 
systems and not as penetration enhancers [55]. 
  
2.4.3. Vesicle adsorption to and/or fusion with the stratum corneum (see Figure 3 at C) 
 The processes of adhesion onto the skin surface and fusion or mixing with the 
lipid matrix of stratum corneum have been suggested for liposome lipids [80].  The 
phospholipid components of liposomes can rapidly enter the skin with the drugs 
following their fate [87]. Phospholipids increased the partitioning of estradiol, 
progesterone and propranolol into the stratum corneum lipid bilayers [88].  It was also 
reported that the phospholipid component of liposomes can increase the continuity of the 
lipid matrix of the skin thus facilitating the movement of lipophilic molecules [89].  
Based on this suggestion, we should expect improved drug uptake from a saturated 
aqueous solution after skin pre-treatment with empty vesicles. Consequently, an uptake 
study was conducted in which stratum corneum membranes were dipped for a short time 
(10 minutes) into medicated vesicles or into an aqueous drug solution with or without 
pre-treatment with empty vesicles [49].  Drug uptake increased only from medicated 
carriers and the uptake ratios (UR) between the vesicles and solution ranged from 23 to 
29 with no significant differences between ultradeformable and standard liposomes. 
Correlating the superiority of ultradeformable vesicles over standard liposomes in 
increasing transepidermal flux, with no significant difference found in the UR at short 
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contact time, suggests that deformable vesicles either improved drug diffusion or 
penetrated deeper in the epidermis, thus allowing more efficient drug clearance 
2.4.4. Intact vesicular skin penetration mechanism (see Figure 3 at D) 
2.4.4.1. Standard liposomes 
 The hypothesis that intact vesicles penetrate through human skin was suggested in 
the first report on liposomes as skin drug delivery systems [12, 19]. It was difficult to 
believe that large lipid vesicles could penetrate the densely packed stratum corneum in 
great numbers.  Accordingly, many researchers have tested this concept with 
controversial findings being reported.  Electron micrography showed the presence of 
intact liposomes in the dermis after application of liposomes loaded with an electron 
dense marker to guinea pigs. The authors proposed that liposomes can penetrate the 
epidermis carrying the drug [27].   
 Liposomal formulations were superior in the treatment of eczema but not for 
psoriasis compared to a traditional gel [90].  This finding suggested that vesicles can 
penetrate diseased skin with its ruptured SC (as in eczema) but cannot invade skin with 
hyperkeratosis, as in psoriasis. Subsequently, fluoromicrographic studies showed that 
intact small unilamellar vesicles (SUVs) containing PC and CH penetrated no deeper than 
the stratum corneum [91]. 
 The ratio of radiolabelled components of liposomal preparations was constant 
throughout the skin strata after topical application of liposomes with dual labelled 
components;  the finding were explained as possible molecular mixing of liposomal 
bilayers with the SC bilayers [59].  The ratio of the radiolabelled marker to liposome 
components was also constant throughout skin strata.  The explanation given by the 
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authors (molecular mixing) may not justify equal ratios of the dual label in the deeper 
skin strata.  These findings may suggest possible carrier skin penetration. Similar findings 
were reported again for both phospholipid and stratum corneum lipid-based liposomes 
[47].   
 In contrast to the above findings, intermediate-sized and not the small liposomes 
resulted in higher skin deposition, indicating that intact liposomes did not penetrate the 
skin [92]. In addition, no evidence of intact carrier penetration could be found after 
application of DMPC or soy-lecithin liposomes [78-79]. 
 The ratio of [
3
H] DPPC to [
14
C] tretinoin deposited into various skin strata of the 
hairless rat was monitored after application of liposome-encapsulated tretinoin.  This 
ratio was constant throughout the SC but not in the nucleated epidermis and dermis.  
Liposomes and tretinoin co-transport into SC was thus accompanied by independent 
penetration of free drug, which could have escaped from liposomes on the skin surface 
[93].  This report suggests that vesicles can penetrate only into the stratum corneum. 
2.4.4.2. Ultradeformable and elastic vesicles 
 Transfersomes have been reported to penetrate the skin intact and go deep enough 
to reach the systemic circulation.  The driving force for Transfersome skin transfer is 
thought to be the natural transdermal hydration gradient.  Phospholipid hydrophilicity 
leads to xerophobia (tendency to avoid dry surrounding).  Accordingly, for the vesicles to 
remain maximally swollen, those on the skin surface will try to follow the local hydration 
gradient, moving into deeper skin strata [13, 52, 65].  
 The process of Transfersome skin penetration was attributed to the vesicle high 
deformability (Figure 4) which is imparted by the presence of edge activator molecules 
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(e.g surfactants) which tend to accumulate at the site of high stress due to their raised 
propensity for greatly curved structures.  This rearrangement reduces the energy required 
for deformation.  The stress is thought to be produced upon drying of the vesicles which, 
being flexible, can follow the transdermal hydration gradient [65]. 
 
Insert Figure 4 
 
 To test this hypothesis, the skin delivery of estradiol from large multi-lamellar 
vesicles (LMLVs, at least 557 nm in diameter) was compared with that obtained from 
smaller vesicles of a mean size of 124-138 nm, (SUVs), assuming that penetration is a 
function of the vesicle size [49].  The tested SUVs were less than the maximum 
dimension reported to enter skin and the minimum size of tested LMLVs was above the 
maximum volume which can invade skin [65].  The SUVs were as effective as LMLVs, a 
finding which suggests that intact vesicles do not permeate through human epidermal 
membrane in vitro [49]. However, it should be noted that the LMLVs were prepared by 
mechanical shaking, a technique which produces heterogeneous populations of vesicles 
(i.e. a mix of smaller and larger sized structures). In more recent studies, reducing vesicle 
size improved drug deposition into deeper strata and penetration through skin, with large 
structures improving deposition only [94-95]. 
 Dipotassium glycyrrhizinate (DG), an amphiphilic anti-inflammatory drug, was 
incorporated into liposomes [96]; DG was reported to increase the elasticity of the carrier.  
Measuring the vesicle size before and after extrusion through a microporous filter, the 
vesicles were capable of penetrating a pore with a diameter three times smaller than their 
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own span. This was taken as evidence for elasticity but the liposomes only improved skin 
deposition of DG, not flux.  This finding provides evidence that vesicles can penetrate 
into but not through skin.  In similar studies, the size of Transfersomes did not change 
after extrusion through semi-permeable membrane barriers. The authors reported the 
presence of the vesicles in mouse blood after topical application of fluorescent labeled 
Transfersomes.  Surprisingly, the size of these vesicles was similar to that of the starting 
liposome suspension.  This was taken evidence for intact vesicle invasion into and 
through skin [97-98].  
 Fast delivery of intact elastic niosomes into the SC was recorded and was thought 
to be via channel-like regions in the SC.  Again, elastic vesicles were superior to rigid 
ones with non-occlusive application being optimum [99]. Monitoring the co-transport of 
vesicle components and a model drug into human skin in vivo, it was found that only 
elastic vesicle materials can rapidly enter the SC reaching almost the SC-viable epidermal 
junction. However, the distribution profile of the drug in the lower SC layers was 
different from that of the vesicle components. This suggests that drug release can take 
place once the elastic vesicles partition into the SC [56]. 
 Based on the above reports, it appears that some vesicles may penetrate intact to 
some extent into healthy skin. However what is not clear is how deep into the skin strata 
intact carriers move, and if indeed intact vesicles can carry their contents through the 
entire tissue and reach the blood stream. 
 
2.4.5. Trans-appendageal penetration (see Fig. 3 at E) 
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 Open application was recommended for optimal transdermal drug delivery from 
Transfersomes, with occlusive application and full skin hydration being detrimental.  
This was attributed to inhibition of the transdermal hydration gradient, which is believed 
to be the driving force for Transfersome-skin penetration [65].  Another possible 
explanation is that occlusion and excessive hydration of the skin can swell the 
corneocytes and thus close or at least minimize the size of shunts that may play a role in 
liposomal skin delivery.   
 Electron microscopy indicated that liposomes up to 600 nm diameter can 
penetrate through skin but those of 1000 nm or more remain interiorised in the SC.  
Deposition depended on the hair density of the skin with higher deposition recorded in 
hairy guinea pigs.  However, with regard to penetration though skin, no difference could 
be found between hairless and hairy guinea pigs.  Despite this, it was concluded that 
invasion is mainly along the hair sheath [100].  However, these findings only reflect 
delivery into, rather than through, the hair follicles.  Other workers excluded vesicular 
delivery through shunts after recording no significant variations between different 
animals or humans with diverse densities of hair follicles, with regard to the 
Transfersomal input of insulin [66]. 
 A novel in vitro technique using human abdominal skin was developed to explore 
the role of appendageal transport on liposomal skin delivery of estradiol.  The proponents 
of this technique utilized a sandwich of SC overlying an entire epidermal membrane 
(including its stratum corneum) and monitored vesicular drug delivery through this 
sandwich compared with the delivery through the epidermis only.  In this system, the 
shunt orifices occupy only a small fraction of the total skin surface area, and thus there is 
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negligible opportunity for the shunts in the two membranes (in the skin sandwich) to 
superimpose.  It was thus assumed that the top layer of SC would block most of the 
shunts available in the bottom membrane [101].  From this study, it was concluded that 
the shunt routes played a minor role in estradiol transdermal delivery from liposomes.  
Another group of researchers recorded enhanced transfollicular delivery from liposomes 
only after combination with iontophoresis [102]. 
 From the above literature, it appears that the shunt routes play no major role in 
liposomal transdermal drug delivery.  However, vesicle penetration into but not 
necessarily through hair follicles (i.e. targeting) is clearly demonstrated by numerous 
literature reports. 
3. Conclusion 
 The potential of different vesicles for dermal and transdermal drug delivery is 
now evident. Recent modifications and structural and composition optimization have 
generated improved therapeutic potential. These modifications resulted in the 
development of flexible and ultradeformable liposomes for which great claims have been 
made with respect of enhanced transdermal drug delivery, including efficiencies 
comparable with subcutaneous administration. Indeed, some claims include noninvasive 
transcutaneous vaccination but the mechanisms of action of these vesicles as skin drug 
delivery systems require further clarification. 
4. Expert opinion 
 The use of vesicles as skin drug delivery systems was proposed almost three 
decades ago with the goal of localizing a corticosteroid in the skin strata, thus reducing its 
systemic side effects. These initial studies utilized standard liposomes made of 
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phospholipids with or without cholesterol. Such liposomes encapsulated mainly small 
organic compounds and rarely macromolecules such as interferon. The recorded effects 
were mainly improved skin deposition and rarely enhanced transdermal delivery. 
Subsequently, considerable interest was directed towards vesicular transdermal drug 
delivery through the introduction of Transfersomes. These were developed by 
incorporating edge activators (surfactants) into the vesicular components to produce 
ultradeformable vesicles. These were claimed to deliver both small and large molecular 
weight compounds including insulin into and through the skin with efficiency similar to 
subcutaneous administration. However, the mechanism of action of these carriers remains 
controversial, especially the claim that intact ultradeformable vesicles can penetrate the 
skin deep enough to reach the systemic circulation with some vesicles detected in the 
blood after topical administration. In parallel to Transfersomes, niosomes were developed 
with the vesicles made of surfactants with cholesterol. These niosomes also showed some 
success in dermal and transdermal delivery and again flexible niosomes appear superior 
to more rigid structures. The elasticity of the vesicular membrane was also achieved by 
incorporating ethanol in the vesicular membrane, producing ethosomes. These 
ultradeformable and elastic vesicles are also claimed to be valuable for non-invasive 
transdermal vaccination.  Taken together, the literature and our own research indicates 
strongly that some types of liposomes can deliver both small and macromolecular 
therapeutic agents to the skin, that delivery through the skin may possibly be increased 
but that some literature claims appear to be rather extravagant.  
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 Despite numerous encouraging reports on flexible and ultradeformable vesicles, 
we think that high vesicle flexibility and deformability is always associated with reduced 
stability, particularly manifested as loss of entrapped material. Not only is this intuitive, 
we have also modeled the geometry of a deformable vesicle as it reconfigures to enter the 
narrow SC lipid domain; on doing so the volume within the liposome cannot be 
conserved so contents must be expelled.  This problem may be partially responsible for 
the lack of deformable vesicular transdermal drug delivery systems in the market. 
Additionally, stability of vesicular systems is problematic, again with respect to drug 
retention during storage.  This is especially problematic for flexible / deformable (i.e. 
fluid) liposomes. One approach to overcome this instability is to minimize the water 
content of the formulation by developing a vesicle pro-concentrate, so called 
proliposomes or proniosomes which contain all the vesicular components with ethanol 
and only traces of water. These systems are gel like preparations which are believed to 
generate vesicles upon application to skin after dilution with skin secretions before 
delivering their contents into and through the skin. However, the application of this 
approach requires further investigation to test the behavior of the vesicles after in situ 
formation. 
 A further issue affecting vesicular system commercialization is problems in 
scaling up, further complicated when considering that the majority of reports utilized 
simple vesicular dispersion with very few authors preparing pharmaceutical formulations 
(e.g. gels or patches). Accordingly, in addition to developing stable liposomes, some 
understanding of realistic formulation design is necessary. Questions remain about 
whether vesicular incorporation into the pharmaceutical dosage form will affect their 
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topical and transdermal drug delivery capacity. This issue will depend on the mechanism 
of action of elastic and deformable vesicle. Despite numerous reports and controversy 
over mechanisms of action, it is widely accepted that intact deformable and flexible 
vesicles can enter human skin to some depth. The next 5 years will show whether small 
and macromolecular delivery via the skin using vesicles is a commercial reality.               
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Fig. 1 Amount of 5-fluorouracil penetrated through human epidermis 36 hours after 
application of Transfersomes or saturated aqueous solution. 
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Fig.2 Transdemal flux (a) and skin deposition (b) of estradiol obtained after open 
application of various vesicular formulations or saturated aqueous solution (control).    
 48 
 
 
 
 
Fig. 3   Possible mechanisms of action of liposomes as skin drug delivery systems. (A) is 
the free drug mechanism, (B) is the penetration enhancing process of liposome 
components, (C) indicates vesicle adsorption to and/or fusion with the stratum corneum 
(SC), (D) illustrates intact vesicle penetration into or into and through the intact skin and 
(E) shows delivery through an appendage (not to scale) (modified from reference [15]). 
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Fig. 4 Hydration gradient and deformability-driven movement of Transfersomes through 
small pores (after Cevc et al., 1996) [103]. 
 
 
 
 
 
 
 
 
